A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Bayer’s asundexian hits phase III stroke goal in win for FXIa drugs
Detailed data will be forthcoming at a scientific congress, but Bayer AG’s positive top-line readout from its phase III study testing oral factor XIa (FXIa) inhibitor a...
Novo’s semaglutide fails in phase III Alzheimer’s trials
Novo Nordisk A/S’ wild card bet that its GLP-1 receptor agonist semaglutide could be used to treat Alzheimer’s disease has not paid off, with the company reporting two...
Novo’s semaglutide fails in phase III Alzheimer’s trials
Novo Nordisk A/S’ wild card bet that its GLP-1 receptor agonist semaglutide could be used to treat Alzheimer’s disease has not paid off, with the company reporting two...
Roche reports positive Phase III data of giredestrant for breast cancer - Clinical Trials Arena
Roche reports positive Phase III data of giredestrant for breast cancer Clinical Trials Arena
Roche sizes up first BTK inhibitor approval on Phase III MS victory - Clinical Trials Arena
Roche sizes up first BTK inhibitor approval on Phase III MS victory Clinical Trials Arena
Roche’s Phase III trial of Gazyva/Gazyvaro for SLE meets primary endpoint - Clinical Trials Arena
Roche’s Phase III trial of Gazyva/Gazyvaro for SLE meets primary endpoint Clinical Trials Arena
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page